Evidence map›Paper›PMID 37131611›Full record

ArticlebioRxiv : the preprint server for biology2023

Engineering Nme2Cas9 Adenine Base Editors with Improved Activity and Targeting Scope.

Nathan Bamidele, Han Zhang, Xiaolong Dong, Nicholas Gaston, Haoyang Cheng, Karen Kelly, Jonathan K Watts, Jun Xie, Guangping Gao, Erik J Sontheimer

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Nathan BamideleRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01605, USA.
Han ZhangRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01605, USA.
Xiaolong DongRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01605, USA.
Nicholas GastonRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01605, USA.
Haoyang ChengRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01605, USA.
Karen KellyRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01605, USA.
Jonathan K WattsRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01605, USA.
Jun XieHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Guangping GaoHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Erik J SontheimerRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01605, USA.

Funding

Enhancing the success of underrepresented students in the biomedical sciencesR25GM113686 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LAPANE, KATE L, LEWIS, BRIAN C · 2015 to 2019
$1.7M
Engineering Synthetic Guide RNAs and Compact Base Editors for Enhanced In Vivo DeliveryF31GM143879 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BAMIDELE, NATHAN · 2021 to 2022
$67k
NIGMS NIH HHS F31 GM143879NIGMS NIH HHS R25 GM113686
6 · The paper itself

Abstract

Nme2Cas9 has been established as a genome editing platform with compact size, high accuracy, and broad targeting range, including single-AAV-deliverable adenine base editors. Here, we have engineered Nme2Cas9 to further increase the activity and targeting scope of compact Nme2Cas9 base editors. We first used domain insertion to position the deaminase domain nearer the displaced DNA strand in the target-bound complex. These domain-inlaid Nme2Cas9 variants exhibited shifted editing windows and increased activity in comparison to the N-terminally fused Nme2-ABE. We next expanded the editing scope by swapping the Nme2Cas9 PAM-interacting domain with that of SmuCas9, which we had previously defined as recognizing a single-cytidine PAM. We used these enhancements to correct two common

Identifiers

PMID37131611
PMCPMC10153126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.